Latest news for Hansa Biopharma (OTC:HNSBF) Stock

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ABCP

AEMD

AFTM

AGFAF

ALTAF

AMRK

ANDR

APAFF

ARXXL

ASPCF

BLOZF

BOSQF

BOTH

BSRC

BTCY

BTSC

BVLDF

BVNNF

CADMF

CBLRF

CLIRF

CLOW

CMGHF

CNBX

CNONF

CONN

COTE

CPNFF

CRNT

CTRM

CTVIF

CWBHF

DAUGF

DOGZ

ELGX

ENDV

ENRT

EVIO

FAMI

FCGD

GALOF

GCFB

GFTX

GGBXF

GLBS

GOSS

GRPBF

GTEC

HEMP

HHPHF

HNSBF

IGRW

INAP

IQST

JILL

JUTOY

KGET

KOPN

LATF

LIXT

LQDA

LTMCF

MDCN

MMJJF

MOGLF

NMHLY

NMKEF

NSUPF

NVSGF

NXTTF

NZRIF

OTEL

OTOW

OZSC

PAOTF

PHUN

PIXY

PMTS

PRRE

PSIX

PTOTF

QRTEA

QRTEB

RETC

RGLSF

RNSFF

SCNNF

SEED

SHLO

SNAVF

SNIRF

SXTC

TCHH

TISUQ

TLRY

Stocks That Hit 52-Week Lows On Tuesday

ACWRF

ADMP

ALLEGIANT GOLD LTD by Allegiant Gold Ltd.

AUXXF

AVPMF

BBAR

BKTPF

BKYI

BTKRF

CEPU

CGTFF

CMCLF

CNPOF

CREX

DKGH

DNJR

DVCR

EGRNY

EMESQ

EOPT

FISOF

GGAL

GLDFF

GTXO

GYNAF

HCCC

HYSR

ITKG

IVITF

JAPAF

LDSYF

LGF-B

LMNR

MFCSF

MGAFF

MJARF

MKTAY

MMDM

MTZPY

NSANF

NSANY

NSPDF

NXES

OLLI

OSBC

OVCHY

PAHC

PDCO

PTNUF

RLLVF

SCOO

SGBX

SPECTRUM GLOBAL SOLUTIONS by Spectrum Global Solutions, Inc.

SGSI

SNNVF

SRHIF

SWDBY

TATT

Telecom Argentina Stet - France Telecom S.A.

THDDY

TTSRF

TWMC

VSBGF

WSTL

XREG

SPPDF

SENS

INDXF

EXSPF

RZREF

MCUIF

QZMRF

Stocks That Hit 52-Week Lows On Thursday

Hansa Biopharma AB

Morgan Stanley analyst Jeffrey Hung upgrades Centessa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) from Equal-Weight to Overweight and raises the price target from $11 to $26.

Upgrades

Price Target

Analyst Ratings

CNTA

Morgan Stanley Upgrades Centessa Pharmaceuticals to Overweight, Raises Price Target to $26

South Korean gaming giant Krafton's recent acquisition of Microsoft Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Tango Gameworks, known for titles like The Evil Within and Hi-Fi Rush, marked a significant move in the <a href="https://www.benzinga.com/general/gaming">gaming sector.</a>
The deal, announced on Aug. 13, was driven more by a commitment to preserving creative talent than by financial incentives.
See Also: <a href="https://www.benzinga.com/general/gaming/24/08/40320631/krafton-saves-tango-gameworks-acquires-hi-fi-rush-ip-from-xbox">Krafton Saves Tango Gameworks: Acquires Hi-Fi Rush IP From Xbox</a>
<h1 class="wp-block-heading">Commitment Over Profit</h1>
&#8220;We don't think Hi-Fi Rush 2 is going to make us money, to be frank,&#8221; CEO Changhan Kim revealed in <a href="https://www.gamedeveloper.com/business/-we-don-t-think-hi-fi-rush-2-is-going-to-make-us-money-krafton-ceo-says-tango-gameworks-acquisition-is-about-legacy">dialogue </a>with Game Developer. 
&#8220;We wanted to maintain their legacy,&#8221; he added. &#8220;Although they did not have a big success in their games, we saw many creatives worth pursuing. That&#8217;s why we wanted to work with that organization.&#8221;
<h1 class="wp-block-heading">Strategic Focus On Hi-Fi Rush</h1>
The acquisition focused specifically on the Hi-Fi Rush intellectual property. 
&#8220;Because Hi-Fi Rush fans really want to see sequels, we negotiated with Tango Gameworks' parent company to acquire that IP as well,&#8221; Kim explained. 
This move was intended to streamline the acquisition process and ensure the game's legacy continued without unnecessary delays.
Kim also addressed the practical aspects of the deal. "If we were to acquire all IPs, I think it's going to complicate the deal too much," he noted. 
<h1 class="wp-block-heading">Staff Transition, Future Plans</h1>
The acquisition involved around 50 of Tango Gameworks&#8217; 100 employees, with the remaining staff not joining Krafton. 
Kim reassured that Krafton had no plans to reduce the new studio's staff and hinted at potential expansion.
&#8220;Krafton is a pretty big company, but Microsoft is very complicated,&#8221; Kim said. &#8220;We wanted to help the team continue developing their games, but especially Hi-Fi Rush.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/05/38791690/xbox-exec-sarah-bond-addresses-microsofts-studio-closures-its-always-extraordinarily-hard-to-make-">Xbox Exec Sarah Bond Addresses Microsoft&#8217;s Studio Closures: &#8216;It&#8217;s Always Extraordinarily Hard To Make Decisions Like That&#8217;</a></li>
</ul>
Photo: Courtesy of Tango Gameworks.

Gaming

MSFT

Why Krafton Bought Tango Gameworks From Microsoft: CEO Kim Reveals 'We Don't Think Hi-Fi Rush 2 Is Going To Make Us Money'

Politan Capital Management (together with its affiliates, "Politan"), a 9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>), today commented on the outcome of the Company's Annual Meeting of Stockholders (the "Annual Meeting").
Both of Politan's independent nominees – Darlene Solomon and William Jellison – were elected to the Board.1 Politan greatly appreciates the support and engagement from its fellow Masimo shareholders during this process.
Darlene Solomon, William Jellison, Michelle Brennan and Quentin Koffey issued the following joint statement:
"While each of us is independent and brings our own unique perspectives, we are united in our enthusiasm for Masimo's future as a leading, innovation-focused growth company. We look forward to meeting with, learning from, and working together with the Healthcare and Consumer employees to make Masimo an even greater company. We would also like customers to know that we will be completely focused on preventing any disruption to their service and support. We will have more to share soon."

Management

MASI

Politan Comments On Results Of Masimo's 2024 Annual Meeting, Both Of Politan's Independent Nominees Darlene Solomon And William Jellison Were Elected To The Board

- Initiation of pivotal CYB003 Phase 3 study in Major Depressive Disorder ("MDD") expected imminently -
- 12-month efficacy data from Phase 2 study of CYB003 in MDD expected in early Q4 2024 -
- Phase 2 topline efficacy and safety results for CYB004 in Generalized Anxiety Disorder ("GAD") expected year-end 2024 or early Q1 2025 -
- Strengthened R&amp;D team with addition of experienced drug development leaders Dr. Atul R. Mahableshwarkar, and Dr. Tom Macek, as program leads for CYB003 and CYB004, respectively -
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cybin.com%2F&amp;esheet=54124810&amp;newsitemid=20240919771162&amp;lan=en-US&amp;anchor=Cybin+Inc.&amp;index=1&amp;md5=66087b8f12a3993545dbd3142c3afc66">Cybin Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#NYSE">CYBN</a>) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported recent clinical accomplishments and key upcoming clinical milestones.

Biotech

CYBN

Cybin Provides Corporate Update On Upcoming Clinical Milestones; Initiation Of Pivotal CYB003 Phase 3 Study In Major Depressive Disorder Expected Imminently; 12-Month Efficacy Data From Phase 2 Study Of CYB003 In MDD Expected In Early Q4 2024; Phase 2 Topline Efficacy And Safety Results For CYB004 In Generalized Anxiety Disorder Expected Year-End 2024 Or Early Q1 2025

Earnings

ASTC

Astrotech FY24 EPS $(7.12) Down From $(5.95) YoY; Revenue $1.66M Up From $750K YoY

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Hansa Biopharma

News

Latest news for Hansa Biopharma (OTC:HNSBF) Stock

Tuesday, December 17, 2019

Thursday, August 29, 2019